Jette A. van Lint
Quality of lifeRisk assessmentInternal medicineIntensive care medicineExact testMedDRACohort studyVedolizumabCertolizumab pegolAzathioprineCombination therapyInfliximabMercaptopurineEtanerceptSummary of Product CharacteristicsInflammatory bowel diseaseSarilumabDiscontinuationUstekinumabDiseaseImmune-mediated inflammatory diseasesSulfasalazineAbataceptAdalimumabAdverse drug reactionNauseaAbdominal painGolimumabDrug reactionHealthcare providersIncidence (epidemiology)PharmacovigilanceMedicineCohortCumulative incidence
5Publications
1H-index
3Citations
Publications 6
Newest
Background: Neuropsychiatric adverse drug reactions (NPADRs) are not commonly associated with low dose methotrexate (LDMTX) in patients with rheumatoid arthritis (RA).Research design and methods: In this case series assessment, we described the nature and frequency of NPADRs with LDMTX in the Dutch DREAM-RA registry, including causality of NPADRs, the impact on further LDMTX treatment and the impact on patient reported Health Related Quality of Life (HRQoL).Results: A total of 71 NPADRs (frequen...
Source
OBJECTIVE We aimed to describe the nature and frequency of gastrointestinal adverse drug reactions (GI-ADRs) of etanercept (ETN) using patient-reported and healthcare professional (HCP)-registered data and compared this frequency with the GI-ADR frequency of the widely used TNFα-inhibitor adalimumab. METHODS Reported GI-ADRs of ETN for rheumatic diseases were collected from the Dutch Biologic Monitor and DREAM registries. We described the clinical course of GI-ADRs and compared the frequency wit...
Source
#1Pepijn W. A. Thomas (Radboud University Nijmegen)H-Index: 2
#2Tessa E H Römkens (Bosch)H-Index: 14
Last. Frank Hoentjen (Radboud University Nijmegen)H-Index: 18
view all 8 authors...
BACKGROUND Only limited data is available on the extent and burden of adverse drug reactions (ADRs) to biological therapy in inflammatory bowel disease (IBD) patients in daily practice, especially from a patient's perspective. OBJECTIVE The aim of this study was to systematically assess patient-reported ADRs during biological therapy in IBD patients and compare these with healthcare provider (HCP)-reported ADRs. METHODS This multicentre, prospective, event monitoring study enrolled IBD patients ...
Source
#1Eline L. GiraudH-Index: 1
#2Ibdream registry (Radboud University Nijmegen)H-Index: 1
Last. Frank Hoentjen (Radboud University Nijmegen)H-Index: 18
view all 11 authors...
INTRODUCTION Inflammatory bowel disease (IBD) frequently requires chronic immunosuppressive treatment and active involvement from patients during treatment decision making. Information about the risk of developing adverse drug reactions (ADRs) to IBD therapies is required in this process. OBJECTIVE The aim of this study was to describe the ADRs reported in IBD patients from real-world data, using the Dutch nationwide IBDREAM registry, and compare the occurrence and cumulative incidences with the...
Source
#1Jette A. van LintH-Index: 1
#2Naomi T. JessurunH-Index: 6
Last. Bart J F van den BemtH-Index: 24
view all 12 authors...
INTRODUCTION Although the burden of adverse drug reactions (ADRs) has a significant impact on patients' quality of life, thorough knowledge about patients' perspectives on the burden of ADRs attributed to biologics is lacking. OBJECTIVES This study was conducted to gain insight into the patient burden of ADRs experienced with biologic use. METHODS The Dutch Biologic Monitor is a prospective, multicentre, event monitoring cohort system including information collected by web-based questionnaires f...
Source
#1Jette A. van LintH-Index: 1
#2Naomi T. JessurunH-Index: 6
Last. Eugène van Puijenbroek (UG: University of Groningen)H-Index: 25
view all 8 authors...
Background: Numerous biological DMARDs (bDMARDs) are used in RA treatment, however detailed knowledge of patients’ perceptions on drug use and the impact of adverse drug reactions (ADRs) is sparse. Objectives: To gain insight into bDMARD-induced ADRs and their burden from the RA patients’ perspective. Methods: The Dutch Biologic Monitor is an ADR-patient web-based questionnaire used for a prospective, multicentre, event monitoring cohort study including patients using a bDMARD for an immune-medi...
Source
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.